15 completed, 7 recruiting, 4 not yet recruiting, 2 unknown. 32 Phase 1, 12 Phase 2.
Follow Neuromyelitis Optica: new trials by email Literature Review of Neuromyelitis Optica trials Research Report on Neuromyelitis Optica
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 20 | 2026-12-01 | 2026-10-16 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 1 | Not yet recruiting | Huashan Hospital | 15 | 2026-02-01 | 2026-01-15 |
| A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders Azercabtagene zapreleucel (azer-cel) - B-cell Mediated Autoimmune Disorders | Phase 1 | Recruiting | TG Therapeutics, Inc. | 100 | 2025-05-06 | 2026-10-27 |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection, A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection - Neuromyelitis Optica Spectrum Disorders | Phase 1 | Recruiting | Tongji Hospital | 69 | 2025-03-28 | 2026-09-21 |
| A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients IMC-002, mycophenolate mofetil, MMF - Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 / Phase 2 | Unknown | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | 116 | 2024-10-10 | 2024-08-16 |
| Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases HBI0101 CART - Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM) | Phase 1 | Recruiting | Polina Stepensky | 120 | 2024-09-01 | 2026-05-06 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM) | Phase 1 | Recruiting | RenJi Hospital | 30 | 2024-03-20 | 2025-07-25 |
| Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica CAR-T cells injection - Neuromyelitis Optica | Phase 1 | Completed | Zhejiang University | 9 | 2023-05-15 | 2025-08-11 |
| Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders Baricitinib - NMO Spectrum Disorder | Phase 1 | Active not recruiting | Tianjin Medical University General Hospital | 11 | 2023-04-15 | 2026-08-11 |
| Ofatumumab in AQP4-IgG Seropositive NMOSD Ofatumumab - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tang-Du Hospital | 5 | 2022-06-28 | 2026-01-30 |
| A Study of LP-168 in Healthy Volunteers LP-168 tablet, LP-168 Placebo tablet - Multiple Sclerosis, NMO Spectrum Disorder | Phase 1 | Completed | Guangzhou Lupeng Pharmaceutical Company LTD. | 70 | 2022-05-14 | 2023-02-24 |
| Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders Belimumab - NMO Spectrum Disorder | Phase 1 / Phase 2 | Completed | Tianjin Medical University General Hospital | 14 | 2021-12-12 | 2024-10-16 |
| A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders BAT4406F - Neuromyelitis Optica Spectrum Disorders | Phase 1 | Completed | Bio-Thera Solutions | 15 | 2020-09-01 | 2025-07-10 |
| A Study of HBM9161 in NMOSD Patients HBM9161 Injection - NMO Spectrum Disorder | Phase 1 | Completed | Harbour BioMed (Guangzhou) Co. Ltd. | 9 | 2020-03-31 | 2022-01-25 |
| Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 Corticosteroids & tanCART19/20 - Neuromyelitis Optica Spectrum Disorder | Phase 1 | Withdrawn | Chinese PLA General Hospital | 2018-08-15 | 2019-09-19 | |
| Central Pain Study for ABX-1431 ABX-1431 HCl, Placebo - Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis | Phase 1 | Completed | Abide Therapeutics | 9 | 2017-08-01 | 2019-01-25 |
Showing 20 of 32. Sign in to see all of them.
Multiple Sclerosis (9) · Myasthenia Gravis (6) · Autoimmune Diseases of the Nervous System (3) · Lupus Erythematosus, Systemic (3) · Multiple Sclerosis, Chronic Progressive (3) · Myelitis, Transverse (3) · Myositis (3) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3) · Scleroderma, Systemic (3) · Optic Neuritis (2) · Stiff-Person Syndrome (2) · Antiphospholipid Syndrome (1) · Arthritis, Rheumatoid (1) · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (1)
Autoimmune Diseases (32) · Cranial Nerve Diseases (32) · Demyelinating Autoimmune Diseases, CNS (32) · Demyelinating Diseases (32) · Eye Diseases (32) · Immune System Diseases (32) · Nervous System Diseases (32) · Optic Nerve Diseases (32) · Optic Neuritis (30) · Autoimmune Diseases of the Nervous System (29) · Myelitis, Transverse (29) · Neoplasms (9) · Neoplasms by Site (9) · Nervous System Neoplasms (9) · Neurodegenerative Diseases (9)
Cyclophosphamide (2) · Methylprednisolone (2) · Methylprednisolone Hemisuccinate (2) · Rituximab (2) · Adrenal Cortex Hormones (1) · Antilymphocyte Serum (1) · Bevacizumab (1) · Cetirizine (1) · Complement C1 Inhibitor Protein (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · HBM9161 (1) · Hematopoietic Stem Cell Transplantation (1) · Immunotherapy, Adoptive (1) · Injections, Spinal (1)
Tianjin Medical University General Hospital (4) · Johns Hopkins University (2) · Tongji Hospital (2) · Abide Therapeutics (1) · Bio-Thera Solutions (1) · CRISPR Therapeutics (1) · Chinese PLA General Hospital (1) · Fu-Dong Shi (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Harbour BioMed (Guangzhou) Co. Ltd. (1) · Huashan Hospital (1) · Icahn School of Medicine at Mount Sinai (1) · ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. (1) · Mayo Clinic (1) · Michael Levy (1)
China (15) · United States (9) · Canada (1) · Israel (1) · Spain (1) · United Kingdom (1)
Michael Levy, MD, PhD (3) · Alexandra L Goodyear, MD, MS (1) · Anu Jacob, MD DM FRCP (1) · Bruce Cree, MD, PhD (1) · Chuan Qin (1) · Chuan Qin, MD (1) · Dai-shi Tian, MD (1) · Daishi Tian (1) · Fu-Dong Shi, MD,PhD (1) · He Huang, MD (1) · Huanfen Zhou, PhD (1) · Ilana Katz Sand, MD (1) · Jacqueline Palace, FRCP DM (1) · Jan Storek, MD,PhD (1) · Jing Zhang (1)